|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-9-30
|
|
pubmed:abstractText |
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way individuals respond has given rise to the concept of 'aspirin resistance.'
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1538-7933
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2340-5
|
|
pubmed:dateRevised |
2010-3-23
|
|
pubmed:meshHeading |
pubmed-meshheading:16150050-Adult,
pubmed-meshheading:16150050-Arachidonic Acid,
pubmed-meshheading:16150050-Aspirin,
pubmed-meshheading:16150050-Cardiovascular Diseases,
pubmed-meshheading:16150050-Cyclooxygenase 1,
pubmed-meshheading:16150050-Cyclooxygenase Inhibitors,
pubmed-meshheading:16150050-Drug Resistance,
pubmed-meshheading:16150050-Female,
pubmed-meshheading:16150050-Haplotypes,
pubmed-meshheading:16150050-Humans,
pubmed-meshheading:16150050-Likelihood Functions,
pubmed-meshheading:16150050-Male,
pubmed-meshheading:16150050-Pharmacogenetics,
pubmed-meshheading:16150050-Platelet Aggregation,
pubmed-meshheading:16150050-Polymorphism, Single Nucleotide,
pubmed-meshheading:16150050-Prospective Studies,
pubmed-meshheading:16150050-Thromboxane A2
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Cyclooxygenase-1 haplotype modulates platelet response to aspirin.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, Royal College of Surgeons, Ireland. amaree@partners.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
